As part of a broader $750 million investment, Deloitte announced Tuesday that it is expanding the firm’s ConvergeHEALTH business. The company plans to expand ConvergeHEALTH’s platforms and efforts in a range of areas, such as improving the patient experience and engagement, helping health systems become more cost-efficient and supporting secure, efficient access to healthcare data.
Author: Praveen Suthrum
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, is pleased to announce that Dr. Carlos Lifschitz has joined Else Nutrition’s Scientific Advisory Board.
Registration is now open for the Gut Microbiota for Health (GMFH) World Summit 2022, taking place March 12-13 in Washington, D.C., and virtually. Organized by AGA and the European Society of Neurogastroenterology and Motility (ESNM), the GMFH World Summit is the preeminent international meeting on the gut microbiome for clinicians, dietitians and researchers.
PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
The colorectal cancer screening market is heating up in 2022, with three large pivotal trials expected to be made public this year, as liquid biopsies in development at Freenome and Guardant Health pose a potential competitive challenge to Exact Sciences’ market-leading Cologuard stool DNA test. Guardant Health CEO Helmy Eltoukhy told MedTech Dive the precision oncology company plans to launch a liquid biopsy for colorectal cancer screening in the first half of the year, called Guardant Shield, and which is meant to challenge Exact Sciences’ Cologuard as well as invasive colonoscopies.
Health inequity is a major challenge to achieving broader social equity and a just society. Interventions to reduce health inequity can be directed at downstream determinants of health, such as individual health-care needs, midstream determinants, such as neighbourhood conditions, or upstream determinants, such as structural racism and discrimination. For example, interventions to reduce inequities in colorectal cancer mortality in African-American people could include mailing reminders about faecal immunochemical tests (downstream intervention); providing patient navigation, transportation, or other direct aid to access health-care services (midstream intervention); or changing laws that redistribute power, wealth, and resources, including health insurance (upstream intervention).
Healio presents the following collection of stories from Crohn’s and Colitis Congress 2022. Topics include the effectiveness of intestinal ultrasound, cultural barriers in inflammatory bowel disease care, therapeutics coming down the IBD pipeline and more. Intestinal ultrasound effective in detecting postoperative Crohn’s recurrence Intestinal ultrasound is an accurate, noninvasive tool in the detection of postoperative Crohn’s disease recurrence, according to research presented at the Crohn’s and Colitis Congress.
Gastrointestinal (GI) endoscopy takes less time when an anesthesiologist oversees the sedation, researchers say. “We have increased patient access to our GI unit by making these modifications,” said Adeel Faruki, MD, a senior instructor of anesthesiology and fellow in operations at the University of Colorado Anschutz Medical Campus in Aurora. The finding was presented at the American Society of Anesthesiologists’ ADVANCE 2022, the Anesthesiology Business Event.
Gastroenterologists who engage in buy and bill are more likely to perform ancillary services than those who do not. “Buy and bill” refers to the process in which a healthcare provider or practice purchases, stores and administers a therapy to a patient, then submits a reimbursement claim to a third-party payer. This data comes from RealTime Dynamix: Ulcerative Colitis (U.S.) fourth quarter. The trends were confirmed in second-quarter and third-quarter data. Gastroenterologists engaging in buy and bill (59 respondents): Two percent do not offer ancillary services.Thirty-one percent choose Janssen as the most supportive to their practice.
Biopsy remains the gold standard for diagnosing nonalcoholic steatohepatitis (NASH). However, the great need for noninvasive tests to risk stratify patients with nonalcoholic fatty liver disease (NAFLD) is beginning to be met, as reflected in the proceedings of The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Following these proceedings, featured expert Rohit Loomba, MD, MHSc, was interviewed by Conference Reporter Editor-in-Chief Tom Iarocci, MD. Dr Loomba’s clinical perspectives are presented here.